A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma

Immunotherapy presents a new promising approach to the treatment of disseminated lung cancer. Pemriblisumab (Kitruda®) is one of the antiPD-1 drugs registered in Russia, which is used in both the secondand, in the event of high-level PD-L1 expression (≥50%), the first-line therapy. This paper presen...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: K. K. Laktionov, D. I. Yudin, K. A. Sarantseva, K. P. Laktionov, V. V. Breder, E. V. Reutova
Format: Artigo
Jezik:Russo
Izdano: Remedium Group LLC 2018-07-01
Serija:Медицинский совет
Teme:
pemribrolizumab
non-small cell lung cancer
pd-1
pd-l1
Online dostop:https://www.med-sovet.pro/jour/article/view/2526
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki